Moby summary of Altimmune, Inc.'s Q4 2025 earnings call ...

Ended 2025 with $1.22 billion in liquidity, bolstered by a $100 million draw from a Royalty Pharma loan facility. Recognized ...

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...

Industry analysts say the arrival of these affordable alternatives—expected to be priced at one-third to one-fifth of the innovator's cost.

Frequent late-night hunger may reflect hormonal shifts, sleep disruption or metabolic conditions rather than poor ...

Novo beat Q4 consensus on revenue and adjusted EPS, driven by 31% obesity-care growth, yet shares fell nearly 40% after a ...

With guests increasingly focused on value and quality while pulling back on overall restaurant spending, we know Sweetgreen, Inc. must deliver on both dimensions without compromising the experience ...

Omada Health (NASDAQ:OMDA) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for standing by. Welcome to the Omada Health Fourth Quarter 2025 Earnings Conference Call.

1 Department of Biochemistry & Biotechnology, Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa. 2 Department of Physiology, Science of Medicine, Sefako Makgatho Health Sciences ...

Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent sign ...